Skip to main content

Day: January 14, 2026

SKYX Announces $4 Million Strategic Investment from Philotimo Fund, LP, Investor in Growing Small-Cap Companies, at $2.00 Per Share in Straight Common with No Warrants

Investment Brings a Total of $14 Million to SKYX in Recent Funding Over the Past 3 Months from Strategic Investors and Long-Term Shareholders as SKYX continues its Market Penetration and Path to Cash Flow Positive MIAMI, Jan. 14, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive smart home platform technology company with over 100 issued and pending patents globally and 60 lighting and home décor websites, with a mission to make homes and buildings become safe, advanced and smart as the new standard, today announced that it has closed a $4 million equity investment from a new institutional fund Philotimo Fund, LP, that invests in growing small-cap companies. The investment was completed at $2.00 per share in straight common stock with no warrants,...

Continue reading

Affidea acquires a majority stake in LabPoint from Lindenhofgruppe, strengthening its diagnostics and laboratory medicine capabilities

Affidea acquires a majority stake in LabPoint from Lindenhofgruppe, strengthening its diagnostics and laboratory medicine capabilitiesAffidea acquires a majority stake in LabPoint from Lindenhofgruppe, strengthening its diagnostics and laboratory medicine capabilitiesTHE HAGUE, The Netherlands, Jan. 14, 2026 (GLOBE NEWSWIRE) — Affidea Group, Europe’s leading provider of advanced diagnostics, community-based polyclinics and specialised healthcare services including oncology, announces the acquisition of a majority stake in LabPoint S.A. from Lindenhofgruppe. LabPoint S.A. is a medical diagnostics laboratory and a recognised player in laboratory medicine, genetics, which, together with Affidea’s capability, will also have integrated pathology and cytology in Switzerland. Founded in 2022 by Lindenhofgruppe, LabPoint has recorded...

Continue reading

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatment for PONV, addressing a critical need in post-surgical care by offering a targeted, effective option to manage this common complication. “This strategic divestiture reflects Eagle Pharmaceuticals commitment to streamlining its acute care business and maximizing value for our shareholders, while ensuring...

Continue reading

Primech AI’s Hytron Featured in Havas Media Network’s CES 2026 Super Stream, Reaching Global Enterprise Audience

Curated inclusion by Havas Media Network highlights Hytron’s relevance to enterprise automation and U.S. commercial deploymentSuper Stream Day 2 at CES 2026 brings together bold ideas, real-world innovation, and human-centered technology shaping the future of brands and media.The day opens with Greg James, CEO of Havas Media Network North America, setting the stage for conversations on AI, creativity, data, and experience. Leaders from Havas and its partners share candid hot takes and deep dives on AI partnerships, performance marketing, customer experience, production, and connected health.Highlights include the Havas Neurverse Activation on the main stage, plus CES floor tours featuring Primech AI, Flint Paper Battery, Naqi Logic, and AARP AgeTech—showcasing how technology is driving impact across robotics, sustainability,...

Continue reading

Tecomet and Orchid Orthopedic Solutions to Merge

Global medical manufacturing combination expected to expand complementary capabilities, strengthen supply continuity and support long-term growthTecometTecomet is a global leader in the design, development and manufacture of MedTech and Aerospace & Defense products.OrchidOrchid provides solutions for procedures in major MedTech markets in the U.S. and Europe.Woburn, MA, and Mason, MI, Jan. 14, 2026 (GLOBE NEWSWIRE) — Tecomet and Orchid Orthopedic Solutions (“Orchid”) today announced that they have entered into a definitive agreement to merge, bringing together highly complementary capabilities to better serve their global customers, expand reach and support long-term growth. Tecomet is a global leader in the design, development and manufacture of MedTech and Aerospace & Defense products. Orchid provides...

Continue reading

Figure Announces the On-chain Public Equity Network (OPEN) Running on Provenance Blockchain

Figure stock will be the first public equity trading native on public blockchain; BitGo, Jump Trading Group sign on to support NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) — Building on the success of over $20 billion in loans originated on public blockchain, Figure has launched the On-Chain Public Equity Network (OPEN), allowing companies to list their equity native on blockchain. Unlike other tokenization efforts, OPEN equities are blockchain registered, not a tokenized version of Depository Trust and Clearing Corporation (DTCC) securities. The equities will trade on a limit order book using Figure’s Alternative Trading System (ATS), opening the door for continuous trading. Shareholders will be able to use Figure’s Democratized Prime, a decentralized finance (DeFi) protocol to borrow against and lend out their stock, disintermediating...

Continue reading

HealthTab™ to Expand Across North East London

VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) — AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) today announced the planned expansion of its HealthTab™ platform across North East London (NEL), with deployment to an additional 70 community pharmacy sites, building on the success of its NHS-linked cardiovascular programmes delivered in collaboration with Barts Health NHS Trust. The programme has attracted national attention, including recent coverage by BBC News highlighting the growing role of community pharmacies in delivering cardiovascular care. The additional sites are expected to be deployed in the coming weeks, reflecting strong pharmacy engagement, increasing clinical demand, and alignment with NHS priorities to shift more care from hospital settings into the community. “This...

Continue reading

GNK Holdings and Marcus Lemonis Submit $1.10 Per Share Non-Binding Proposal to Acquire BARK, Inc.

All-Cash Offer Reflects 22% Premium to Great Dane Ventures Proposal NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) — GNK Holdings LLC, together with Marcus Lemonis (collectively, the “Group”), today announced that they have submitted a preliminary, non-binding indication of interest to acquire BARK, Inc. (NYSE: BARK) (“BARK” or the “Company”) in an all-cash transaction valued at $1.10 per share. The proposed transaction would value BARK at an implied enterprise value of approximately $188.7 million, representing a 22% premium to the previously announced proposal by Great Dane Ventures, LLC. Under the terms of the GNK proposal, the Group would acquire all outstanding shares of BARK not already owned by members of the Group, subject to customary conditions and confirmatory due diligence. The Group is led by GNK Holdings alongside Marcus...

Continue reading

Minerals Technologies Inc. Announces Paper and Packaging Satellite Expansions in Asia

— Four new paper and packaging satellites in China and India; doubled capacity at an additional site in India — — 50% of Asia expansions dedicated to packaging applications — NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) — Minerals Technologies Inc. (NYSE: MTX) (“MTI”), a leading, technology-driven specialty minerals company, today announced an expansion of its paper and packaging business in Asia that included the startup of three new satellite plants in 2025, the doubling of capacity at an existing satellite, and the expected commissioning of an additional new satellite in early 2026. These investments underscore MTI’s commitment to growth across markets and to helping customers cost-effectively produce high-quality products, improve productivity, and drive sustainable practices. MTI’s paper and packaging satellite...

Continue reading

Virtu Financial to Host Conference Call Announcing Fourth Quarter 2025 Results on Thursday, January 29, 2026

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NYSE:VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to the global markets, will announce its results for the fourth quarter of 2025 on Thursday, January 29, 2026, before the US market open. Virtu will host a conference call to discuss the company’s financial results at 8:00 AM (ET). A live webcast of the event will be available and archived on the Investor Relations section of the company’s website at https://ir.virtu.com/events-presentations. The call will be open to the public. About Virtu Financial, Inc.Virtu is a leading provider of financial services and products that leverages cutting-edge technology to deliver liquidity to the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.